# OnCo record rocapuldencel-t (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/rocapuldencel-t/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "rocapuldencel-t" ;
  schema:name "Rocapuldencel-T"@en ;
  schema:alternateName "AGS-003"@en, "AGS-003-LNG"@en, "AGS-003-BLD"@en ;
  schema:description "Rocapuldencel-T is an individualised autologous dendritic cell immunotherapy from Argos Therapeutics that reached phase 3 for metastatic renal cell carcinoma; development has stopped."@en ;
  schema:url <https://onco.cc/drugs/rocapuldencel-t/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://www.sec.gov/Archives/edgar/data/1105533/000117184318002425/f10k_040218p.htm>, <https://www.sec.gov/Archives/edgar/data/1105533/000117184318008023/f10q_111918p.htm>, <https://www.sec.gov/Archives/edgar/data/1105533/000117184318008263/f8k_113018.htm>, <https://clinicaltrials.gov/api/v2/studies/NCT01582672>, <https://clinicaltrials.gov/search?intr=AGS-003> ;
  onco:status "phase-3" ;
  onco:tag "pipeline", "ctgov-ingest", "discontinued" ;
  onco:modality "Individualised autologous dendritic cell immunotherapy (Arcelis platform)" ;
  onco:cancers <https://onco.cc/cancers/rcc/> ;
  onco:companies <https://onco.cc/companies/argos-therapeutics/> ;
  onco:trials <https://onco.cc/trials/nct01582672/>, <https://onco.cc/trials/nct00678119/>, <https://onco.cc/trials/nct00272649/>, <https://onco.cc/trials/nct01482949/>, <https://onco.cc/trials/nct02170389/>, <https://onco.cc/trials/nct02662634/>, <https://onco.cc/trials/nct02944357/> .